Guang-Yu Liu
Overview
Explore the profile of Guang-Yu Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Wu H, Gong Y, Ji P, Xie Y, Jiang Y, Liu G
J Hematol Oncol
. 2022 Apr;
15(1):45.
PMID: 35477416
Targeting nucleotide metabolism can not only inhibit tumor initiation and progression but also exert serious side effects. With in-depth studies of nucleotide metabolism, our understanding of nucleotide metabolism in tumors...
22.
Guo J, Liu G, Wang R, Sun S
Molecules
. 2022 Mar;
27(6).
PMID: 35335248
Imidazole and tetrazole derivatives are widely used as clinical drugs since they possess a variety of pharmaceutical function. Zinc and iron are essential trace elements of the human body, with...
23.
Chen L, Jiang Y, Wu S, Wu J, Di G, Liu G, et al.
Clin Cancer Res
. 2022 Mar;
28(13):2807-2817.
PMID: 35247906
Purpose: Camrelizumab, an mAb against programmed cell death protein 1 (PD-1), plus nab-paclitaxel exhibited promising antitumor activity in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC). Famitinib is a tyrosine kinase...
24.
Wu H, Lu Y, Li J, Wu S, Chen X, Liu G
Front Oncol
. 2022 Feb;
11:791995.
PMID: 35198434
Introduction: Locoregional recurrent breast cancer indicates poor prognosis. No solid prediction model is available to predict prognosis and guide clinical management. Prior local treatment or systemic treatment remains controversial. Methods:...
25.
Yang F, Wu S, Mo M, Xiao Q, Yang X, Liu Y, et al.
Transl Cancer Res
. 2022 Feb;
9(1):155-165.
PMID: 35117169
Background: To investigate ipsilateral breast tumor recurrence (IBTR) in patients who have undergone breast-conserving surgery (BCS) after neoadjuvant systematic therapy (NST). Method: Three hundred and twenty-one patients undergoing BCS after...
26.
Shen Z, Tang C, Liu G
Mil Med Res
. 2022 Jan;
9(1):3.
PMID: 35012680
Bacteria can evolve rapidly by acquiring new traits such as virulence, metabolic properties, and most importantly, antimicrobial resistance, through horizontal gene transfer (HGT). Multidrug resistance in bacteria, especially in Gram-negative...
27.
Liu Y, Liu H, Yu T, Lu Q, Zhang F, Liu G, et al.
Cell Death Differ
. 2022 Jan;
29(4):861-873.
PMID: 34974534
MORC family CW-type zinc finger 2 (MORC2) is a newly identified chromatin-remodeling enzyme involved in DNA damage response and gene transcription, and its dysregulation has been linked with Charcot-Marie-Tooth disease,...
28.
Cui X, Wang L, Liu G, Xie Y
Zhongguo Zhong Yao Za Zhi
. 2021 Dec;
46(21):5450-5455.
PMID: 34951195
Pharmacovigilance system is an extension of the original adverse drug reactions monitoring and reporting system as well as an internationally recognized basic system that must be matched with the whole...
29.
Qu F, Mao R, Liu Z, Lin C, Cao A, Wu J, et al.
Front Oncol
. 2021 Sep;
11:690658.
PMID: 34527574
Background: Loco-regional recurrences (LRR) following breast-conserving surgery (BCS) remain a heterogeneous class of disease that has significant variation in its biological behavior and prognosis. Methods: To delineate the spatiotemporal patterns...
30.
Yu K, Liu X, Chen L, Mo M, Wu J, Liu G, et al.
Lancet Reg Health West Pac
. 2021 Jul;
11:100158.
PMID: 34327363
Background: De-escalating anthracycline is gaining popularity for breast cancer patients. We aim to evaluate the non-inferiority of an anthracycline-free or short-term regimen to the standard anthracycline-based regimen for operable patients...